Chromatin context-dependent effects of epigenetic drugs on CRISPR-Cas9 editing
Nucleic Acids Research · 27.08.2024 · 52 (15) · 8815-8832
DOI: 10.1093/nar/gkae570 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 02.07.2024. Verfasst von Ruben Schep und 10 weiteren Autor:innen. Beteiligte Einrichtung: Oncode Institute, The Netherlands. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Gene Editing, Epigenesis, Genetic, Chromatin. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: ZonMW TOP, The Dutch Cancer Society, EU/MUR MSCA Young Researcher Fellowship.
Abstract (Originalsprache)
The efficiency and outcome of CRISPR/Cas9 editing depends on the chromatin state at the cut site. It has been shown that changing the chromatin state can influence both the efficiency and repair outcome, and epigenetic drugs have been used to improve Cas9 editing. However, because the target proteins of these drugs are not homogeneously distributed across the genome, the efficacy of these drugs may be expected to vary from locus to locus. Here, we systematically analyzed this chromatin context-dependency for 160 epigenetic drugs. We used a human cell line with 19 stably integrated reporters to induce a double-stranded break in different chromatin environments. We then measured Cas9 editing efficiency and repair pathway usage by sequencing the mutational signatures. We identified 58 drugs that modulate Cas9 editing efficiency and/or repair outcome dependent on the local chromatin environment. For example, we find a subset of histone deacetylase inhibitors that improve Cas9 editing efficiency throughout all types of heterochromatin (e.g. PCI-24781), while others were only effective in euchromatin and H3K27me3-marked regions (e.g. apicidin). In summary, this study reveals that most epigenetic drugs alter CRISPR editing in a chromatin-dependent manner, and provides a resource to improve Cas9 editing more selectively at the desired location.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Oncode Institute, The Netherlands.
- Division of Molecular Genetics, 1066 CX Amsterdam, The Netherlands.
- Division of Cell Biology, 1066 CX Amsterdam, The Netherlands.
- Division of Molecular Carcinogenesis, 1066 CX Amsterdam, The Netherlands.
- Division of Oncogenomics, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
- Laboratory of Chemical Biology and Institute for Complex Molecular Systems, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands.
ORCID-Profile: Ruben Schep, Max Trauernicht, Xabier Vergara, Anoek Friskes, Sebastian Gregoricchio, Stefano G Manzo, Wilbert Zwart, Roderick L Beijersbergen, René H Medema, Bas van Steensel
Förderung
- ZonMW TOP
- The Dutch Cancer Society
- EU/MUR MSCA Young Researcher Fellowship
- European Research Council
- KWF Dutch Cancer Society
Zitieren
APA
Schep, R., Trauernicht, M., Vergara, X., Friskes, A., Morris, B., Gregoricchio, S., Manzo, S. G., Zwart, W., Beijersbergen, R. L., Medema, R. H., & van Steensel, B. (2024). Chromatin context-dependent effects of epigenetic drugs on CRISPR-Cas9 editing. Nucleic Acids Research, 52(15), 8815-8832. https://doi.org/10.1093/nar/gkae570
Vancouver
Schep R, Trauernicht M, Vergara X, Friskes A, Morris B, Gregoricchio S, et al. Chromatin context-dependent effects of epigenetic drugs on CRISPR-Cas9 editing. Nucleic Acids Research. 2024;52(15):8815-8832. doi:10.1093/nar/gkae570
BibTeX
@article{Schep2024,
author = {Schep, Ruben and Trauernicht, Max and Vergara, Xabier and Friskes, Anoek and Morris, Ben and Gregoricchio, Sebastian and Manzo, Stefano G and Zwart, Wilbert and Beijersbergen, Roderick L and Medema, René H and van Steensel, Bas},
title = {Chromatin context-dependent effects of epigenetic drugs on CRISPR-Cas9 editing},
journal = {Nucleic Acids Research},
year = {2024},
volume = {52},
number = {15},
pages = {8815--8832},
doi = {10.1093/nar/gkae570}
}
EUVIMED